{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:30:10Z","timestamp":1788485410338,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901942"],"award-info":[{"award-number":["81901942"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971481"],"award-info":[{"award-number":["81971481"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170364"],"award-info":[{"award-number":["82170364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170612"],"award-info":[{"award-number":["82170612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["A2020264"],"award-info":[{"award-number":["A2020264"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.livres.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T18:42:22Z","timestamp":1682966542000},"page":"136-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-7274","authenticated-orcid":false,"given":"Li-Li","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Shuo","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-4416","authenticated-orcid":false,"given":"Zhi-Liang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2023.04.002_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2023.04.002_bib2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2023.04.002_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.intimp.2017.02.019","article-title":"Th17\/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B","volume":"46","author":"Liu","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.livres.2023.04.002_bib4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2023.04.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.livres.2020.02.005","article-title":"Functional cure of chronic hepatitis b: efforts and prospects","volume":"4","author":"Mo","year":"2020","journal-title":"Liver Res"},{"key":"10.1016\/j.livres.2023.04.002_bib6","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.livres.2023.04.002_bib7","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib8","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2023.04.002_bib9","article-title":"2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2023.04.002_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib11","first-page":"25","article-title":"HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog:new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jvh.13722","article-title":"Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients","volume":"29","author":"Chu","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2023.04.002_bib14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jvh.13734","article-title":"Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy","volume":"29","author":"Gao","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2023.04.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198657","article-title":"Transforming growth factor-\u03b2: an early predictor of a functional cure in chronic hepatitis B treated with interferon","volume":"309","author":"Wu","year":"2022","journal-title":"Virus Res"},{"key":"10.1016\/j.livres.2023.04.002_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","article-title":"TNF-\u03b1\/IFN-\u03b3 profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection","volume":"72","author":"Wang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory T cells: differentiation and function","volume":"4","author":"Plitas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.livres.2023.04.002_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.livres.2023.04.002_bib19","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jiab216","article-title":"Pegylated interferon-\u0251 (IFN-\u0251) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-\u03b3 in chronic hepatitis B","volume":"224","author":"Yuan","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.livres.2023.04.002_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/653496","article-title":"Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes","volume":"202","author":"Kondo","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.livres.2023.04.002_bib21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.25765","article-title":"Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice","volume":"56","author":"Stross","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2023.04.002_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","article-title":"A\u00a0CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis","volume":"389","author":"Groux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.livres.2023.04.002_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7520605","article-title":"Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis","volume":"265","author":"Chen","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.livres.2023.04.002_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/ijms19030730","article-title":"The balance of Th17 versus Treg cells in autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.livres.2023.04.002_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12873","article-title":"Regulatory T cells and T helper 17 cells in viral infection","volume":"91","author":"Wan","year":"2020","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.livres.2023.04.002_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jgh.12082","article-title":"Imbalance of interleukin-17-producing CD4 T cells\/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure","volume":"28","author":"Zhang","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12967-017-1167-y","article-title":"Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis","volume":"15","author":"Li","year":"2017","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.livres.2023.04.002_bib28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.livres.2023.04.002_bib29","article-title":"Effect of WSP, a Chinese herbal formula, on Th17\/Treg ratio and HBeAg seroconversion in telbivudine-treated HBeAg-positive chronic hepatitis B patients with high baseline ALT levels (20-30 times the ULN)","author":"Zhang","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.livres.2023.04.002_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/vim.2016.0007","article-title":"Low ratio of Treg to Th17 cells after 36 weeks of telbivudine therapy predict HBeAg seroconversion","volume":"29","author":"Wang","year":"2016","journal-title":"Viral Immunol"},{"key":"10.1016\/j.livres.2023.04.002_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jvh.12152","article-title":"Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)\/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B","volume":"21","author":"Li","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2023.04.002_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9140602","article-title":"Treg\/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages","author":"Tan","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.livres.2023.04.002_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13000-019-0891-4","article-title":"Treg\/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis","volume":"14","author":"Lan","year":"2019","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.livres.2023.04.002_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jgh.12459","article-title":"Ratios of regulatory T cells\/T-helper 17 cells and transforming growth factor-\u03b21\/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis","volume":"29","author":"Yu","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib35","article-title":"Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2023.04.002_bib36","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15332","article-title":"Dynamic changes of Treg and Th17 cells and related cytokines closely correlate with the virological and biochemical response in chronic hepatitis B patients undergoing nucleos(t)ide analogues treatment","volume":"13","author":"Yu","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.livres.2023.04.002_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.diagmicrobio.2013.04.026","article-title":"Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B","volume":"76","author":"Su","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.livres.2023.04.002_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"Thimme","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/vim.2015.0024","article-title":"Sustained changes of Treg and Th17 cells during interferon-\u03b1 therapy in patients with chronic hepatitis B","volume":"28","author":"Feng","year":"2015","journal-title":"Viral Immunol"},{"key":"10.1016\/j.livres.2023.04.002_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103464","article-title":"Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss","volume":"69","author":"Xiong","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.livres.2023.04.002_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated interferon \u03b1-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2023.04.002_bib43","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jiab216","article-title":"Pegylated interferon-\u0251 (IFN-\u0251) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-\u03b3 in chronic hepatitis B","volume":"224","author":"Yuan","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.livres.2023.04.002_bib44","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.livres.2023.04.002_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.intimp.2018.06.043","article-title":"Recovery of circulating CD56dim NK cells and the balance of Th17\/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg","volume":"62","author":"Liu","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.livres.2023.04.002_bib46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/jhep.2001.23045","article-title":"Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy","volume":"33","author":"Boni","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2023.04.002_bib47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2023.04.002_bib48","article-title":"CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2023.04.002_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50729-5","article-title":"Soluble immune markers in the different phases of chronic hepatitis B virus infection","volume":"9","author":"Wiegand","year":"2019","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1016\/j.livres.2023.08.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568423000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568423000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:21:02Z","timestamp":1762629662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568423000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2542568423000181"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2023.04.002","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}